The Significance of Prior Benign Needle Biopsies in Men Subsequently Diagnosed With Prostate Cancer

Epstein, Jonathan I.; Walsh, Patrick C.; Akingba, George; Carter, H. Ballentine

doi:10.1016/s0022-5347(05)68189-x

Cited by 43 publications

(17 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies have reported that patients with repeat biopsies had high total PV. 7,[19][20][21] A study by Raventó s et al 22 also revealed that PV was an independent predictor for diagnosing CIPC, as in our study. Therefore, it is suggested that the PV definitively affected the detection of CIPC.…”

Section: Discussionsupporting

confidence: 87%

Detection rate of clinically insignificant prostate cancer increases with repeat prostate biopsies

Park¹,

Jeon²,

Ju³

et al. 2012

Asian J Androl

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 87%

Detection rate of clinically insignificant prostate cancer increases with repeat prostate biopsies

Park¹,

Jeon²,

Ju³

et al. 2012

Asian J Androl

View full text Add to dashboard Cite

“…Djavan et al [47] showed that patients with multifocal disease could be reliably differentiated from patients with unifocal disease with a sensitivity of 90% using transition-zone PSA density and ratio of free to total PSA. In addition, Epstein et al [48] found that tumors are more likely to be multifocal when biopsies are diagonally positive (ie, left apex, right mid) or horizontally positive (ie, left apex, right apex) than when they are vertically positive (ie, left apex, left mid). Also, optimization of biopsy protocols can greatly diminish the chances of missing a significant multifocal tumor.…”

Section: Quality Of Lifementioning

confidence: 99%

The current and potential role of cryoablation as a primary therapy for localized prostate cancer

Katz

Rewcastle²

2003

Curr Oncol Rep

View full text Add to dashboard Cite

Targeted cryoablation of the prostate has evolved significantly since its reintroduction in the early 1990s. This evolution stems from engineering advancements, procedural refinement, introduction of temperature monitoring, and greater understanding of cryobiology. Recent publications demonstrate durable efficacy for cryoablation, equivalent to other therapies for low-risk disease and possibly superior for moderate- and high-risk prostate cancer. Morbidity following the procedure is mild in comparison with other therapies, with the exception of sexual function impairment. However, longer-term quality-of-life studies show that a significant number of patients return to having intercourse, and late-onset morbidities are not observed. These results contrast with those for radiotherapy--specifically brachytherapy--for which several recent studies document a decline in sexual function, protracted morbidity, and the emergence of late-onset morbidity. Cryoablation is an effective therapy with acceptable morbidity that should be offered as a treatment option to all patients with localized prostate cancer. Furthermore, cryoablation has the potential ability to be tailored to an individual patient's disease. As diagnostic tools and methods continue to advance, it may become possible to target the less aggressive forms of prostate cancer. Focal cryoablation may prove to be an ideal treatment modality in this setting.

show abstract

“…Traditional techniques may miss substantial numbers of cancers, creating a high false-negative rate at initial biopsy. The saturation technique explores the transitional and lateral peripheral zone where cancers are found more frequently in patients who had a previously negative biopsy [17] . Interestingly, a saturation technique strategy at initial assessment may also decrease the false-negative rate and reduce indications of repeat biopsy.…”

Section: Discussionmentioning

confidence: 99%

Extended Biopsy Protocol Decreases Prostate Cancer Incidence and Risk of Aggressive Disease on Repeated Biopsies Compared with Initial Standard Procedure

Ploussard

Bastien²,

Descazeaud³

et al. 2010

Urol Int

View full text Add to dashboard Cite

Objectives: To compare prostate cancer detection rates in repeated biopsy depending on the number of cores at initial biopsy. Methods: Out of 3,000 consecutive patients, 534 underwent repeat extended biopsies. At first procedure, 345 patients had undergone standard biopsies (10–15 cores; SBx) whereas 189 other patients had already had a 21-core extended protocol (ExtBx). Clinicobiological and pathological parameters were compared between 2 groups. Results: The prostate cancer detection rate was significantly higher in the SBx group (37%) compared with the ExtBx group (16.8%, p < 0.001). Mean PSA level, mean percent free PSA and mean prostate volume were equivalent in both groups. Thirty-eight percent of cancers detected in the SBx group were graded Gleason 7 or more, compared with 19.3% in the ExtBx group (p = 0.018). Mean percent of core invasion was 25.3% in the SBx group compared to 15.9% in the ExtBx group (p = 0.004). Conclusions: A full evaluation of all prostate zones using ExtBx seems to be necessary to decrease the risk of undetected prostate cancer on repeated biopsies. For patients who had at their first biopsy an ExtBx, the risk of prostate cancer on the repeated biopsies and the risk of aggressive cancer were lower compared to standard biopsies.

show abstract

The Significance of Prior Benign Needle Biopsies in Men Subsequently Diagnosed With Prostate Cancer

Cited by 43 publications

References 20 publications

Detection rate of clinically insignificant prostate cancer increases with repeat prostate biopsies

Detection rate of clinically insignificant prostate cancer increases with repeat prostate biopsies

The current and potential role of cryoablation as a primary therapy for localized prostate cancer

Extended Biopsy Protocol Decreases Prostate Cancer Incidence and Risk of Aggressive Disease on Repeated Biopsies Compared with Initial Standard Procedure

Contact Info

Product

Resources

About